For people with multiple sclerosis (MS) on Ocrevus (ocrelizumab) whose disease is well controlled after at least a year of treatment, discontinuing the infusion therapy does not appear to increase the risk of new disease activity or disability progression for about two years. That’s according to a new retrospective study from Germany, in which researchers investigated […]
The post Stopping Ocrevus in stable MS doesn’t seem to raise 2-year risk, study finds appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com